Thus, CERo's technology has the potential to overcome major barriers to successful
adoptive cell therapy by combining direct cell killing and phagocytic antigen
presentation into single T cells to achieve tumor control.
With respect to tumor-associated barriers, eat me signals, unlike protein antigens,
are not under genetic control. Thus, tumor heterogeneity in terms of target expression,
which can lead to escape of target-negative cells, is unlikely to be a potential cause
of relapse with CER T-cell therapy.
CER T cells also have the potential to overcome tumor microenvironmental immune suppression.
One mechanism by which tumor cells escape immune surveillance is by disabling the process
of tumor antigen uptake, processing, and presentation, resulting in poor cytotoxic anti-tumor
immune responses. The additional APC-like activity of CER T cells has the capacity to prime
tumor-specific cytotoxic T cells, leading to a robust secondary immune response sufficient
for tumor eradication. Indeed, studies have shown that infiltration of T cells, especially
CD8 T cells into tumor microenvironment, correlates with better prognosis in multiple
malignancies such as lymphoma, breast, lung, melanoma, colorectal, and brain cancer.
Learn More About our CER Technology Platform
